BR112014019274A2 - métodos relacionados ao tratamento de doenças e distúrbios inflamatórios - Google Patents

métodos relacionados ao tratamento de doenças e distúrbios inflamatórios

Info

Publication number
BR112014019274A2
BR112014019274A2 BR112014019274A BR112014019274A BR112014019274A2 BR 112014019274 A2 BR112014019274 A2 BR 112014019274A2 BR 112014019274 A BR112014019274 A BR 112014019274A BR 112014019274 A BR112014019274 A BR 112014019274A BR 112014019274 A2 BR112014019274 A2 BR 112014019274A2
Authority
BR
Brazil
Prior art keywords
disorders
inflammatory diseases
treatment
methods related
methods
Prior art date
Application number
BR112014019274A
Other languages
English (en)
Inventor
Steensgaard Frederiksen Klaus
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112014019274A2 publication Critical patent/BR112014019274A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "métodos relacionados ao tratamento de doenças e distúrbios inflamatórios". a presente invenção refere-se a métodos dentro do campo de diagnóstico, prognóstico e otimização de tratamento de doenças e distúrbios inflamatórios e marcadores gênicos associados a um método para predição da resposta clínica em um paciente que sofre de doenças ou distúrbios inflamatórios.
BR112014019274A 2012-02-10 2013-02-11 métodos relacionados ao tratamento de doenças e distúrbios inflamatórios BR112014019274A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12154917 2012-02-10
US201261597924P 2012-02-13 2012-02-13
PCT/EP2013/052629 WO2013117751A2 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders

Publications (1)

Publication Number Publication Date
BR112014019274A2 true BR112014019274A2 (pt) 2017-06-27

Family

ID=48948117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019274A BR112014019274A2 (pt) 2012-02-10 2013-02-11 métodos relacionados ao tratamento de doenças e distúrbios inflamatórios

Country Status (8)

Country Link
EP (1) EP2812445A2 (pt)
KR (1) KR20140124767A (pt)
CN (1) CN104204230A (pt)
AU (1) AU2013217940A1 (pt)
BR (1) BR112014019274A2 (pt)
CA (1) CA2864133A1 (pt)
MX (1) MX2014009490A (pt)
WO (1) WO2013117751A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230003433A (ko) 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045261A2 (en) 1999-12-07 2001-06-21 Parthus Technologies Plc Model for charge pump phase-locked loop
JP2003535037A (ja) 1999-12-23 2003-11-25 ザイモジェネティクス，インコーポレイティド 炎症を治療する方法
DE10227527A1 (de) 2002-06-20 2004-01-08 Clariant Gmbh Verfahren zur Herstellung von Disazopigmenten
US7435800B2 (en) 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
WO2005052001A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2007006858A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
IES20050495A2 (en) 2005-07-20 2006-11-01 Minroc Techn Promotions Ltd A drill bit assembly for fluid-operated percussion drill tools
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
WO2007081465A2 (en) 2005-12-09 2007-07-19 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
WO2008048986A2 (en) * 2006-10-17 2008-04-24 Children's Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
WO2008056198A1 (en) 2006-11-09 2008-05-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
EP2132343B1 (en) * 2007-03-01 2012-08-29 Université Catholique de Louvain Method for the determination and the classification of rheumatic conditions
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
SG182183A1 (en) 2007-06-08 2012-07-30 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
CA2735155A1 (en) 2008-08-28 2010-03-04 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
EP3235509A1 (en) 2009-03-05 2017-10-25 AbbVie Inc. Il-17 binding proteins
DK2414542T3 (da) * 2009-03-30 2017-11-27 Tel Hashomer Medical Res Infrastructure & Services Ltd Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
CN102597268B (zh) 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
US8580528B2 (en) * 2009-10-16 2013-11-12 Stichting Vu-Vumc Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
WO2011154139A2 (en) * 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment

Also Published As

Publication number Publication date
AU2013217940A1 (en) 2014-07-31
CA2864133A1 (en) 2013-08-15
MX2014009490A (es) 2014-08-29
EP2812445A2 (en) 2014-12-17
WO2013117751A2 (en) 2013-08-15
WO2013117751A3 (en) 2013-10-03
KR20140124767A (ko) 2014-10-27
CN104204230A (zh) 2014-12-10

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112014011127A2 (pt) métodos para tratar, diagnosticar e monitorar doença de alzheimer
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
MX350010B (es) Inhibidores syk de imidazopiridinas.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
EA201390150A1 (ru) Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
WO2012170704A3 (en) Methods and compositions of predicting activity of retinoid x receptor modulator
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
IN2014DN08398A (pt)
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
BR112015030099A2 (pt) marcador para desordens de esfingomielinase ácida e usos do mesmo
BR112015027249A2 (pt) método de diagnóstico de câncer
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
EA201490548A1 (ru) Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)